AG
ANIP icon

Advisor Group’s ANI Pharmaceuticals ANIP Stock Holding History

Advisor Group’s Portfolio ANIP Stock Details ANIP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		$81K Buy
1,312
+14
+1% +$927 ﹤0.01% 3076
2019
Q3 		$94K Sell
1,298
-129
-9% -$9.65K ﹤0.01% 2924
2019
Q2 		$117K Sell
1,427
-338
-19% -$24K ﹤0.01% 2739
2019
Q1 		$124K Sell
1,765
-364
-17% -$21.4K ﹤0.01% 2668
2018
Q4 		$96K Sell
2,129
-243
-10% -$12.7K ﹤0.01% 2680
2018
Q3 		$134K Buy
2,372
+965
+69% +$59.1K ﹤0.01% 2524
2018
Q2 		$94K Sell
1,407
-11
-0.8% -$687 ﹤0.01% 2570
2018
Q1 		$83K Sell
1,418
-381
-21% -$24.2K ﹤0.01% 2694
2017
Q4 		$116K Sell
1,799
-66
-4% -$4.11K ﹤0.01% 2452
2017
Q3 		$97K Buy
1,865
+115
+7% +$5.48K ﹤0.01% 2428
2017
Q2 		$81K Buy
1,750
+304
+21% +$14.7K ﹤0.01% 2476
2017
Q1 		$71K Buy
1,446
+264
+22% +$14.8K ﹤0.01% 2421
2016
Q4 		$71K Sell
1,182
-42
-3% -$2.57K ﹤0.01% 2312
2016
Q3 		$82K Buy
1,224
+1,074
+716% +$67.2K ﹤0.01% 2136
2016
Q2 		$8K Buy
+150
New +$7.29K ﹤0.01% 3566

Other funds holding ANIP

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ICOM
Investment Counselors of Maryland Baltimore, Maryland $4.37B AUM 76.25% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

Advisor Group's ANIP Position: Q4 2019 in Review

Advisor Group increased its ANI Pharmaceuticals (ANIP) stake by 1.1% in Q4 2019, buying an estimated $927 and bringing the position to 1,312 shares worth $81K. The position accounts for ﹤0.01% of the portfolio, ranked #3076.

Advisor Group first reported a position in ANIP in Q2 2016 and has held it in 15 quarters since. The position peaked at $134K in Q3 2018. 170 funds tracked by Wall St. Rank hold ANIP as of Q4 2019.

  • Advisor Group held 1,312 shares of ANI Pharmaceuticals worth $81K as of Q4 2019.
  • Advisor Group bought 14 ANI Pharmaceuticals shares in Q4 2019, an estimated $927.
  • ANI Pharmaceuticals made up ﹤0.01% of Advisor Group's portfolio in Q4 2019, its #3076 holding.
  • Advisor Group first reported a position in ANI Pharmaceuticals in Q2 2016 and has held it in 15 quarters since.
  • Advisor Group's ANI Pharmaceuticals position peaked at $134K in Q3 2018.
  • 170 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q4 2019.

Based on Advisor Group's 13F filing for Q4 2019, filed 12 Feb 2020.